{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:26:20Z","timestamp":1770823580718,"version":"3.50.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1378\/chest.07-1381","type":"journal-article","created":{"date-parts":[[2007,9,14]],"date-time":"2007-09-14T18:23:17Z","timestamp":1189794197000},"page":"277S-289S","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":132,"special_numbering":"S","title":["Treatment of Non-small Cell Lung Cancer, Stage IV"],"prefix":"10.1016","volume":"132","author":[{"given":"Mark A.","family":"Socinski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Crowell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Hensing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey J.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogerio","family":"Lilenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan B.","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1378\/chest.07-1381_bib1","unstructured":"Cancer facts and figures2006 American Cancer Society. Atlanta, GA"},{"key":"10.1378\/chest.07-1381_bib2","first-page":"45","article-title":"Clinical presentation and diagnosis","author":"Detterbeck","year":"2001"},{"key":"10.1378\/chest.07-1381_bib3","doi-asserted-by":"crossref","first-page":"226S","DOI":"10.1378\/chest.123.1_suppl.226S","article-title":"Chemotherapeutic management of stage IV non-small cell lung cancer","volume":"123(suppl)","author":"Socinski","year":"2003","journal-title":"Chest"},{"key":"10.1378\/chest.07-1381_bib4","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jama.292.4.470","article-title":"Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis","volume":"292","author":"Delbaldo","year":"2004","journal-title":"JAMA"},{"key":"10.1378\/chest.07-1381_bib5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2005.07.172","article-title":"Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the Cancer and Leukemia Group B (study 9730)","volume":"23","author":"Lilenbaum","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib6","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1200\/JCO.2004.11.004","article-title":"Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial","volume":"22","author":"Georgoulias","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib7","doi-asserted-by":"crossref","first-page":"8380","DOI":"10.1200\/JCO.2005.01.2781","article-title":"Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group","volume":"23","author":"Sederholm","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib8","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group","volume":"21","author":"Fossella","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2005.03.2722","article-title":"Adding gemcitabine to paclitaxel\/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II\u2013III study","volume":"24","author":"Paccagnella","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib10","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.2003.12.038","article-title":"Cisplatin plus gemcitabine (CG) vs a cisplatin-based triplet vs nonplatinum sequential doublets in advanced non-small cell lung cancer (NSCLC): a Spanish Lung Cancer Group phase III randomized trial (GEPC\/98-02)","volume":"21","author":"Alberola","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial; INTACT 1","volume":"22","author":"Giaccone","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib12","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial; INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib14","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.07-1381_bib15","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ssu.2980100106","article-title":"Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data","volume":"10","author":"Ries","year":"1994","journal-title":"Semin Surg Oncol"},{"key":"10.1378\/chest.07-1381_bib17","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1200\/JCO.2004.05.031","article-title":"Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from Surveillance, Epidemiology and End Results-Medicare","volume":"22","author":"Ramsey","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib18","first-page":"1335","article-title":"Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB\/IV non-small-cell lung cancer","volume":"20","author":"Socinski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/jnci\/91.1.66","article-title":"Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer: the Elderly Lung Cancer Vinorelbine Italian Study Group","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1378\/chest.07-1381_bib20","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/jco.2005.23.16_suppl.7009","article-title":"Randomized phase III study of docetaxel (D) versus vinorelbine (V) for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): results of a West Japan Thoracic Oncology Group trial (WJTOG9904)","volume":"23(suppl)","author":"Takeda","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib21","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2000.18.13.2529","article-title":"Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer","volume":"18","author":"Frasci","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jnci\/95.5.362","article-title":"Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial","volume":"95","author":"Gridelli","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1378\/chest.07-1381_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jnci\/94.3.173","article-title":"Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial","volume":"94","author":"Langer","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1378\/chest.07-1381_bib24","first-page":"639","article-title":"Age-specific subanalysis of ECOG 1594: fit elderly patients (70\u201380 yrs) with NSCLC do as well as younger patients (<70) [abstract]","volume":"22","author":"Langer","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.07-1381_bib26","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/cncr.21495","article-title":"Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326)","volume":"104","author":"Belani","year":"2005","journal-title":"Cancer"},{"key":"10.1378\/chest.07-1381_bib27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/cncr.11548","article-title":"The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel","volume":"98","author":"Hensing","year":"2003","journal-title":"Cancer"},{"key":"10.1378\/chest.07-1381_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.seminoncol.2004.10.002","article-title":"Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancer","volume":"31(suppl)","author":"Langer","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1378\/chest.07-1381_bib29","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.3816\/CLC.2004.s.017","article-title":"Treatment of patients with advanced lung cancer and poor performance status","volume":"6(suppl)","author":"Lilenbaum","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"10.1378\/chest.07-1381_bib30","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8","article-title":"Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma","volume":"92","author":"Sweeney","year":"2001","journal-title":"Cancer"},{"key":"10.1378\/chest.07-1381_bib31","first-page":"627","article-title":"ECOG 1599: randomized phase II study of paclitaxel\/carboplatin or gemcitabine\/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC) [abstract]","volume":"23","author":"Tester","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib32","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1023\/A:1012208711013","article-title":"Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine","volume":"12","author":"Vansteenkiste","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1378\/chest.07-1381_bib33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.1998.437","article-title":"Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors","volume":"78","author":"Hickish","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1378\/chest.07-1381_bib34","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/thx.2003.020164","article-title":"Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life","volume":"59","author":"Spiro","year":"2004","journal-title":"Thorax"},{"key":"10.1378\/chest.07-1381_bib35","doi-asserted-by":"crossref","first-page":"7417","DOI":"10.1200\/JCO.2005.09.158","article-title":"Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer","volume":"23","author":"Brown","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0169-5002(99)00017-3","article-title":"Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy","volume":"24","author":"Thongprasert","year":"1999","journal-title":"Lung Cancer"},{"key":"10.1378\/chest.07-1381_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1023\/A:1015048908822","article-title":"Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial","volume":"11","author":"Moinpour","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1378\/chest.07-1381_bib38","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1200\/JCO.1994.12.6.1113","article-title":"Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B","volume":"12","author":"Kosty","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<333::AID-CNCR10>3.0.CO;2-Q","article-title":"Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?","volume":"85","author":"Herndon","year":"1999","journal-title":"Cancer"},{"key":"10.1378\/chest.07-1381_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0169-5002(94)00392-Z","article-title":"The patient's perception of his own quality of life might have an adjunctive prognostic significance in lung cancer","volume":"12","author":"Buccheri","year":"1995","journal-title":"Lung Cancer"},{"key":"10.1378\/chest.07-1381_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1026442201191","article-title":"Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy; the National Cancer Institute of Canada Clinical Trials Group","volume":"6","author":"Dancey","year":"1997","journal-title":"Qual Life Res"},{"key":"10.1378\/chest.07-1381_bib42","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0885-3924(95)00056-5","article-title":"Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer","volume":"10","author":"Degner","year":"1995","journal-title":"J Pain Symptom Manage"},{"key":"10.1378\/chest.07-1381_bib43","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1023\/B:QURE.0000037481.36604.eb","article-title":"Baseline FACT-G score is a predictor of survival for advanced lung cancer","volume":"13","author":"Dharma-Wardene","year":"2004","journal-title":"Qual Life Res"},{"key":"10.1378\/chest.07-1381_bib44","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1002\/1097-0142(19910615)67:12<3131::AID-CNCR2820671232>3.0.CO;2-4","article-title":"Quality of life assessment: an independent prognostic variable for survival in lung cancer","volume":"67","author":"Ganz","year":"1991","journal-title":"Cancer"},{"key":"10.1378\/chest.07-1381_bib45","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/jjco\/28.12.749","article-title":"Quality of life (QOL) assessment of MIP (mitomycin, ifosfamide and cisplatin) chemotherapy in advanced non-small cell lung cancers (NSCLC)","volume":"28","author":"Han","year":"1998","journal-title":"Jpn J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0167-8140(89)90091-1","article-title":"Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease: the importance of patients' subjective experience of disease and psychosocial well-being","volume":"15","author":"Kaasa","year":"1989","journal-title":"Radiother Oncol"},{"key":"10.1378\/chest.07-1381_bib47","doi-asserted-by":"crossref","first-page":"324S","DOI":"10.1378\/chest.106.6_Supplement.324S","article-title":"Quality of life in lung cancer surgical adjuvant trials","volume":"106(suppl)","author":"Ruckdeschel","year":"1994","journal-title":"Chest"},{"key":"10.1378\/chest.07-1381_bib48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0167-8140(00)00158-4","article-title":"The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy","volume":"55","author":"Langendijk","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1378\/chest.07-1381_bib49","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1200\/JCO.1994.12.3.601","article-title":"Prospective evaluation of prognostic variables from patient-completed questionnaires: North Central Cancer Treatment Group","volume":"12","author":"Loprinzi","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib50","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0169-5002(00)00179-3","article-title":"Quality of life in lung cancer patients: as an important prognostic factor","volume":"31","author":"Montazeri","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1378\/chest.07-1381_bib51","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<724::AID-CNCR9>3.0.CO;2-D","article-title":"Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion","volume":"79","author":"Tester","year":"1997","journal-title":"Cancer"},{"key":"10.1378\/chest.07-1381_bib52","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1200\/JCO.2005.02.527","volume":"23","author":"Maione","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib53","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1200\/JCO.2003.07.128","article-title":"Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592","volume":"21","author":"Eton","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib54","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","article-title":"Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non\u2013small-cell lung cancer: a Southwest Oncology Group trial","volume":"19","author":"Kelly","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib55","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.2000.18.3.623","article-title":"Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial","volume":"18","author":"Bonomi","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib56","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<333::AID-CNCR10>3.0.CO;2-Q","article-title":"Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?","volume":"85","author":"Herndon","year":"1999","journal-title":"Cancer"},{"key":"10.1378\/chest.07-1381_bib57","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1378\/chest.127.3.738","article-title":"Significant progress in palliative treatment of non-small cell lung cancer in the past decade","volume":"127","author":"Waechter","year":"2005","journal-title":"Chest"},{"key":"10.1378\/chest.07-1381_bib58","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/bmj.317.7161.771","article-title":"Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews","volume":"317","author":"Silvestri","year":"1998","journal-title":"BMJ"},{"key":"10.1378\/chest.07-1381_bib59","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0738-3991(01)00155-0","article-title":"Cancer patients' attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision support","volume":"45","author":"Brundage","year":"2001","journal-title":"Patient Educ Couns"},{"key":"10.1378\/chest.07-1381_bib60","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/jama.279.21.1709","article-title":"Relationship between cancer patients' predictions of prognosis and their treatment preferences","volume":"279","author":"Weeks","year":"1998","journal-title":"JAMA"},{"key":"10.1378\/chest.07-1381_bib61","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1191\/026921601680419429","article-title":"Receiving a diagnosis of lung cancer: patients' interpretations, perceptions and perspectives","volume":"15","author":"Yardley","year":"2001","journal-title":"Palliat Med"},{"key":"10.1378\/chest.07-1381_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-5002(97)00048-2","article-title":"Do doctors know when their patients don't? A survey of doctor-patient communication in lung cancer","volume":"18","author":"Quirt","year":"1997","journal-title":"Lung Cancer"},{"key":"10.1378\/chest.07-1381_bib63","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0954-6111(05)80315-4","article-title":"Communicating the diagnosis of lung cancer","volume":"87","author":"Sell","year":"1993","journal-title":"Respir Med"},{"key":"10.1378\/chest.07-1381_bib64","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1378\/chest.117.5.1239","article-title":"Who gets chemotherapy for metastatic lung cancer?","volume":"117","author":"Earle","year":"2000","journal-title":"Chest"},{"key":"10.1378\/chest.07-1381_bib65","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.2004.02.051","article-title":"Population variations in the initial treatment of non-small-cell lung cancer","volume":"22","author":"Potosky","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib66","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.1995.13.8.1904","article-title":"Does knowledge guide practice? Another look at the management of non-small-cell lung cancer","volume":"13","author":"Raby","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib67","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1336::AID-CNCR9>3.0.CO;2-M","article-title":"Patterns of practice survey for nonsmall cell lung carcinoma in the U.S","volume":"88","author":"Choy","year":"2000","journal-title":"Cancer"},{"key":"10.1378\/chest.07-1381_bib68","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1200\/JCO.2001.19.5.1326","article-title":"Phase I study of a decision aid for patients with locally advanced non-small-cell lung cancer","volume":"19","author":"Brundage","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib69","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/(SICI)1099-1611(199911\/12)8:6<511::AID-PON415>3.0.CO;2-T","article-title":"Lung cancer treatment decisions: patients' desires for participation and information","volume":"8","author":"Davidson","year":"1999","journal-title":"Psychooncology"},{"key":"10.1378\/chest.07-1381_bib70","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/pon.2960040305","article-title":"No news is not good news: information preferences of patients with cancer","volume":"4","author":"Fallowfield","year":"1995","journal-title":"Psychooncology"},{"key":"10.1378\/chest.07-1381_bib71","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/bmj.313.7059.724","article-title":"Information needs of cancer patients in west Scotland: cross sectional survey of patients' views","volume":"313","author":"Meredith","year":"1996","journal-title":"BMJ"},{"key":"10.1378\/chest.07-1381_bib72","first-page":"149","article-title":"Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer","volume":"3","author":"Dubey","year":"2005","journal-title":"J Support Oncol"},{"key":"10.1378\/chest.07-1381_bib73","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11136-005-0581-4","article-title":"Are chemotherapy patients' HRQoL importance weights consistent with linear scoring rules? A stated-choice approach","volume":"15","author":"Johnson","year":"2006","journal-title":"Qual Life Res"},{"key":"10.1378\/chest.07-1381_bib74","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.2005.03.170","article-title":"Phase III study of matrix metalloproteinase inhibitor prinomastat in non- small-cell lung cancer","volume":"23","author":"Bissett","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib75","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.lungcan.2004.05.009","article-title":"Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer","volume":"46","author":"Douillard","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1378\/chest.07-1381_bib76","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/annonc\/mdh031","article-title":"Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer","volume":"15","author":"Gatzemeier","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1378\/chest.07-1381_bib77","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1200\/JCO.2005.04.044","article-title":"Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR. 18","volume":"23","author":"Leighl","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib78","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/cncr.11535","article-title":"Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma","volume":"98","author":"Danson","year":"2003","journal-title":"Cancer"},{"key":"10.1378\/chest.07-1381_bib79","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-5002(02)00076-4","article-title":"Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study","volume":"37","author":"Gebbia","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1378\/chest.07-1381_bib80","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2005.03.037","article-title":"Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group","volume":"23","author":"Rudd","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.07-1381_bib81","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/cncr.10174","article-title":"Therapy choices among older patients with lung carcinoma","volume":"94","author":"Rocha Lima","year":"2002","journal-title":"Cancer"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215355252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215355252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:53:44Z","timestamp":1757919224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215355252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S0012369215355252"],"URL":"https:\/\/doi.org\/10.1378\/chest.07-1381","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Non-small Cell Lung Cancer, Stage IV","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.07-1381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}